National Cancer Institute CRO Aviano

CHEMIOTHERAPY: IMATINIB DRUG MONITORING

Posted by National Cancer Institute CRO AvianoResponsive · Patents for licensing · Italy

Summary of the technology

The effectiveness of many anticancer drugs varies greatly from patient to patient, with risks of incorrect dosages and adverse side effects. The invention provides for the first time an electrochemical method to measure the concentration of the drug Imatinib in patient's plasma and then to establish the optimal dose, with an on site test readable in real time.

Description of the technology

Imatinib is an anticancer drug used in particular for the treatment of Philadelphia chromosome positive acute lymphoblastic leukemia. The therapeutic drug monitoring greatly improves the effectiveness of the cancer treatment and helps to personalize the doses and to limit side effects.

Quick procedures are therefore essential. The patented electrochemical method provides a simple, fast and cost effective protocol for the measurement of Imatinib concentration through plasma collection; said method is suitable for the manufacturing of a device, that will make the test results readily and easily accessible at the patient's bed (point of care), avoiding long times required by specialized analysis.

The method involves the selective extraction of the drug on a liquid liquid extraction column and a following measurement of its concentration using an electrochemical technique, in particular adsorptive stripping voltammetry.

Intellectual property status

Patent already applied for
102019000008808

Technology Owner

National Cancer Institute CRO Aviano

Research Institute

Additional information (attached documents)

Related keywords

  • Pharmaceutical Products / Drugs
  • Therapeutic services
  • Oncology
  • point of care
  • chemotherapy
  • electrochemistry
  • imatinib

About National Cancer Institute CRO Aviano

Research Institute from Italy

National Cancer Institute CRO-Aviano is an Italian public institute funded in 1984 and is committed to pursue excellence in all aspects of clinical oncology and management of health services. CRO is also an excellence in translational and clinical research activity. Our structure performs an average of 378740 patient exams/year, 8295 pts admitted/year (50% are extra-regional) for medium-long term stays and day hospital treatment. Scientific production sets above of 230 scientific papers in journals with Impact Factor (IF), ranking in the set of the 10% most cited papers in their respective scientific field, having a total IF>1000. Clinical trials average 60 per year.

Send your request

By clicking "Send your request" you are signing up and accepting our Terms of Service and Privacy policy

Technology Offers on Innoget are directly posted and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.